Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score (Q34450910)

2 August 2017

Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score (English)

1 reference

Primary systemic amyloidosis

2 August 2017

1 reference

4

David Dingli

1 reference

2 August 2017

15

Angela Dispenzieri

1 reference

2 August 2017

13

Robert A Kyle

1 reference

2 August 2017

3

Martha Q Lacy

1 reference

2 August 2017

12

Stephen J Russell

1 reference

2 August 2017

14

S Vincent Rajkumar

1 reference

2 August 2017

2

Morie A Gertz

1 reference

2 August 2017

5

Suzanne R Hayman

1 reference

2 August 2017

8

Steven R Zeldenrust

1 reference

2 August 2017

11

John A Lust

1 reference

2 August 2017

6

Francis K Buadi

1 reference

2 August 2017

1

Shaji K Kumar

1 reference

2 August 2017

10

Philip R Greipp

1 reference

2 August 2017

Kristen Short-Detweiler

series ordinal

7

1 reference

PubMed ID

21193650

2 August 2017

Nelson Leung

series ordinal

9

1 reference

PubMed ID

21193650

2 August 2017

language of work or name

English

0 references

publication date

1 January 2011

1 reference

2 August 2017

1 reference

2 August 2017

86

1 reference

2 August 2017

12-18

1 reference

2 August 2017

1

1 reference

Treatment of immunoglobulin light chain amyloidosis

2 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Serum uric acid: novel prognostic factor in primary systemic amyloidosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Improved survival in multiple myeloma and the impact of novel therapies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

"Primary" systemic amyloidosis and myeloma. Discussion of relationship and review of 81 cases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

AL amyloidosis: the last 30 years

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients with congestive heart failure.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012628

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

9 December 2018

1 reference

12 December 2020

Hyperuricaemia in patients with right or left heart failure

1 reference

12 December 2020

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

1 reference

12 December 2020

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

1 reference

12 December 2020

Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey

1 reference

12 December 2020

Diagnosing primary amyloidosis

1 reference

12 December 2020

High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study

1 reference

12 December 2020

Identifiers

DOI

10.4065/MCP.2010.0480

1 reference

2 August 2017

1 reference

2 August 2017

1 reference

PubMed ID

21193650